Clinical Trial Update: 18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: a Pilot Study [EARLY_Phase 1]

View source ↗

Summary

An EARLY Phase 1 pilot study evaluating the 18F-rhPSMA-7.3 PET/MRI tracer for prostate cancer under active surveillance has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 18F-rhPSMA-7.3 (rhPSMA-7.3 radiotracer)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Prostate Cancer | EARLY_Phase 1 | Status: WITHDRAWN